3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Breast Neoplasms
3
Carcinoma, Basal Cell
2
Breast Diseases
2
Basal Cell Nevus Syndrome
2
Thrombocythemia, Essential
1
Polycythemia Vera
1
Hypogonadism
1
Glioma
1
Gastric Adenocarcinoma
1
Fatigue Syndrome, Chronic
1
Eunuchism
1
Colorectal Neoplasms
1
Interventions
fludarabine phosphate
16
Cyclophosphamide
15
Peripheral Blood Stem Cell Transplantation
10
Tacrolimus
9
Busulfan
9
Whole-Body Irradiation
8
Mycophenolic Acid
8
fludarabine
6
Methotrexate
6
Cyclosporine
6
Radiotherapy
5
ruxolitinib
4
Biopsy
4
Antilymphocyte Serum
4
Specimen Handling
3
Decitabine
3
peginterferon alfa-2a
2
givinostat hydrochloride
2
givinostat
2
bomedemstat
2
Stem Cell Transplantation
2
Prednisone
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
Methylprednisolone
2
Melphalan
2
Imatinib Mesylate
2
Filgrastim
2
Etoposide
2
Cytarabine
2
Aspirin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Thrombocythemia, Essential
×
Drug Evaluation
×
Clear all
NCT02577926
2025-06-10
Ruxo-BEAT
RWTH Aachen University
Phase 2
Active not recruiting
207 enrolled